Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003243 | Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00004871 | Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 |
| Mar 10, 2010 |
| clinicaltrials |
| NCT00006042 | Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00015925 | MS-275 in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00077558 | 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT01078337 | T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis | completed | — | 15 | Stanford UniversityOTHER | 1 | Mar 2, 2010 | clinicaltrials |
| NCT00017342 | Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia | completed | Phase 2 | — | Virginia Commonwealth UniversityOTHER | 1 | Mar 1, 2010 | clinicaltrials |
| NCT00003187 | Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma | completed | Phase 2 / Phase 3 | 19 | Virginia Commonwealth UniversityOTHER | 1 | Feb 24, 2010 | clinicaltrials |
| NCT00005580 | Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma | completed | Phase 1 | 54 | Virginia Commonwealth UniversityOTHER | 1 | Feb 24, 2010 | clinicaltrials |
| NCT00003079 | Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma | completed | Phase 1 | 30 | Virginia Commonwealth UniversityOTHER | 1 | Feb 17, 2010 | clinicaltrials |
| NCT00834002 | Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission(CCRG 05-001) | completed | Phase 1 | 10 | University Hospital, AntwerpOTHER | 1 | Feb 9, 2010 | clinicaltrials |
| NCT00298987 | A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate | completed | Phase 2 | 400 | Bristol-Myers SquibbINDUSTRY | 2 | Feb 8, 2010 | clinicaltrials |
| NCT01063660 | Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML) | completed | Phase 2 | 75 | medac GmbHINDUSTRY | 1 | Feb 5, 2010 | clinicaltrials |
| NCT00464217 | Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years | completed | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 5, 2010 | clinicaltrials |
| NCT00526305 | LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive | completed | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 5, 2010 | clinicaltrials |
| NCT00180102 | AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years | completed | Phase 4 | 600 | Technische Universität DresdenOTHER | 1 | Dec 24, 2009 | clinicaltrials |
| NCT01034839 | High-dose Cytarabine and Survival in AML | completed | — | 499 | University of Sao Paulo General HospitalOTHER | 1 | Dec 18, 2009 | clinicaltrials |
| NCT00292760 | A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion | completed | Phase 2 | — | Royal Marsden NHS Foundation TrustOTHER | 0 | Dec 16, 2009 | clinicaltrials |
| NCT00363974 | Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML | completed | Phase 1 / Phase 2 | 54 | Aegera TherapeuticsINDUSTRY | 2 | Dec 1, 2009 | clinicaltrials |
| NCT01020175 | Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation | completed | Phase 3 | 350 | European Society for Blood and Marrow TransplantationNETWORK | 1 | Nov 25, 2009 | clinicaltrials |
| NCT00081926 | Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 4 | 112 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT01015196 | Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation(AML2001) | completed | Phase 2 / Phase 3 | 832 | Nantes University HospitalOTHER | 1 | Nov 18, 2009 | clinicaltrials |
| NCT00195533 | Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients | completed | — | 801 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Nov 16, 2009 | clinicaltrials |
| NCT00021749 | Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 40 | Genta IncorporatedINDUSTRY | 1 | Nov 13, 2009 | clinicaltrials |
| NCT00042016 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | completed | Phase 2 | 40 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 14, 2009 | clinicaltrials |
| NCT00006246 | Busulfan in Treating Children and Adolescents With Refractory CNS Cancer | completed | Phase 1 | 28 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Oct 7, 2009 | clinicaltrials |
| NCT00631579 | Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma | completed | Phase 2 | 50 | SanofiINDUSTRY | 1 | Oct 2, 2009 | clinicaltrials |
| NCT00512083 | Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia | completed | Phase 2 | 70 | Antisoma ResearchINDUSTRY | 2 | Sep 25, 2009 | clinicaltrials |
| NCT00415103 | AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors(AMENO-2) | completed | Phase 4 | 196 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00401739 | Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia | completed | Phase 1 | 40 | CSL LimitedINDUSTRY | 1 | Sep 16, 2009 | clinicaltrials |
| NCT00530699 | Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 30 | AstraZenecaINDUSTRY | 1 | Sep 11, 2009 | clinicaltrials |
| NCT00037583 | Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia | completed | Phase 2 | 69 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Aug 21, 2009 | clinicaltrials |
| NCT00962767 | Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission | completed | Phase 3 | 168 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Aug 20, 2009 | clinicaltrials |
| NCT00373373 | Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML | completed | Phase 2 | 200 | University Hospital MuensterOTHER | 1 | Aug 19, 2009 | clinicaltrials |
| NCT00304447 | Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia | completed | Phase 4 | 30 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Jul 29, 2009 | clinicaltrials |
| NCT00759837 | Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects | completed | Phase 1 | 27 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 16, 2009 | clinicaltrials |
| NCT00931138 | Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2(ALFA 9801) | completed | Phase 3 | 420 | Acute Leukemia French AssociationOTHER | 1 | Jul 2, 2009 | clinicaltrials |
| NCT00925873 | GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly | completed | Phase 3 | 303 | French Innovative Leukemia OrganisationOTHER | 1 | Jun 22, 2009 | clinicaltrials |
| NCT00352677 | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | completed | Phase 1 | 100 | CytRxINDUSTRY | 3 | Jun 1, 2009 | clinicaltrials |
| NCT00494897 | PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia | completed | Phase 4 | 374 | PETHEMA FoundationOTHER | 1 | May 19, 2009 | clinicaltrials |
| NCT00391014 | Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis(AMBINEB) | completed | Phase 2 | 150 | PETHEMA FoundationOTHER | 1 | May 12, 2009 | clinicaltrials |
| NCT00036023 | Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies | completed | Phase 2 | — | AmgenINDUSTRY | 0 | May 11, 2009 | clinicaltrials |
| NCT00055146 | Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 41 | Eisai Inc.INDUSTRY | 5 | Apr 17, 2009 | clinicaltrials |
| NCT00880243 | Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML) | completed | Phase 3 | 473 | Acute Leukemia French AssociationOTHER | 0 | Apr 13, 2009 | clinicaltrials |
| NCT00064584 | Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 24, 2009 | clinicaltrials |
| NCT00866073 | Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia | completed | Phase 2 | 238 | University Hospital FreiburgOTHER | 2 | Mar 20, 2009 | clinicaltrials |
| NCT00452257 | A Study of Enzastaurin in Patients With Leukemia | completed | Phase 1 | 18 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 19, 2009 | clinicaltrials |
| NCT00850304 | Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide | completed | Phase 2 | 10 | Tehran University of Medical SciencesOTHER | 1 | Feb 24, 2009 | clinicaltrials |
| NCT00257647 | Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) | completed | — | 25 | Hadassah Medical OrganizationOTHER | 1 | Feb 18, 2009 | clinicaltrials |
| NCT00145613 | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | completed | Phase 2 | 25 | St. Jude Children's Research HospitalOTHER | 1 | Feb 13, 2009 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2010source: clinicaltrials